Aurobindo Pharma's Subsidiary Unit Undergoes US FDA Inspection, Receives OAI Classification
Aurobindo Pharma Limited announced that its wholly owned subsidiary, Eugia Pharma Specialities Ltd., underwent an inspection by the United States Food and Drug Administration (US FDA). The inspection was conducted at the company's formulation manufacturing facility in Telangana, leading to a classification of 'official action indicated' (OAI).The inspection of Unit-I, a Formulation manufacturing facility belonging to Eugia Pharma Specialities Ltd., was carried out by the US FDA between February 16 and February 27, 2026. The inspection concluded with four observations.
The US FDA subsequently determined that the classification for the facility is 'official action indicated' (OAI).
The following table summarizes the details regarding the inspection and the action taken by the US FDA.
| Particulars | Details |
|---|---|
| Authority | US Food and Drug Administration (US FDA), USA |
| Facility | Unit-I, Formulation manufacturing facility, of Eugia Pharma Specialities Ltd. |
| Location | Kolthur Village, Shameerpet Mandal, Ranga Reddy, 500078, Telangana |
| Inspection Period | February 16 to February 27, 2026 |
| Observations | The inspection concluded with 4 observations. |
| Action Taken | FDA determined the inspection classification is 'official action indicated' (OAI). |
| Financial Impact | There is no impact on the Company's financials or operations due to the said action. |
Aurobindo Pharma Limited affirmed its commitment to maintaining the highest quality manufacturing standards across all its global facilities. The company noted that there is no impact on its financials or operations arising from the US FDA action.
AUROPHARMA Stock Price Movement
On Friday, Aurobindo Pharma Limited shares slipped by 5.09% to settle at ₹1463.50. The stock traded on a volume of 3.04 million shares, falling significantly from its previous day’s close of ₹1546.70.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.